Imatinib mesylate
BCR-ABL inhibitor / Imatinib is a tyrosine kinase inhibitor specific for abl (IC50 = 0.038 µM)1, PDGF-R (IC50 = 0.3 µM)1 and c-kit (IC50 = 0.1 µM)2. It is a clinically useful anti-cancer drug approved for the treatment of chronic myelogenous leukemia, gastrointestinal stromal tumors as well as several other cancers.
Biochemicals & reagents
220127-57-1
Gleevec; STI571
1) Buchdunger, et al.(1996) Inhibition of the Abl Protein-Tyrosine Kinase in Vitro and in Vivo by a 2-Phenylpyrimidine Derivative; Cancer Res. 56, 100 / 2) Heinrich et al (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96 925.
-20°C
TARGET: Kinase; Cytochrome/MDR -- PATHWAY: Autophagy -- RESEARCH AREA: Cell death -- DISEASE AREA: Cancer